Core Laboratories CLB Deferred Compensation Liability (Non-Current)
Deferred Compensation Liability (Non-Current) at other companies
Other financials
Where this comes from
Reported directly by Core Laboratories in its filing.
Tagged under the XBRL concept us-gaap:DeferredCompensationLiabilityClassifiedNoncurrent.
The official record: Core Laboratories’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Core Laboratories's deferred compensation liability (non-current).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is Core Laboratories's deferred compensation liability (non-current)?
- Core Laboratories (CLB) reported deferred compensation liability (non-current) of $28.17M in Q1 2026.
- How has Core Laboratories's deferred compensation liability (non-current) changed year-over-year?
- Core Laboratories's deferred compensation liability (non-current) decreased by 3.5% year-over-year, from $29.2M to $28.17M.
- What is the long-term trend for Core Laboratories's deferred compensation liability (non-current)?
- Over 3 years (2022 to 2025), Core Laboratories's deferred compensation liability (non-current) has grown at a -2.6% compound annual growth rate (CAGR), from $31.81M to $29.38M.
- What does deferred compensation liability (non-current) mean?
- This metric captures the long-term portion of liabilities arising from employee compensation plans where payment is deferred to future periods beyond one year. It reflects the company's commitment to settle these obligations, such as executive retirement benefits or long-term incentive plans, at a later date. Tracking this liability is essential for understanding the company's long-term financial leverage and future cash flow commitments related to human capital.